Опухоль матки, гистологически схожая с овариальными опухолями полового тяжа — редкое новообразование, разделяющееся на две группы: эндометриальная стромальная опухоль с очагами опухоли полового тяжа (ESTSCLE, тип I) и опухоль матки, напоминающая овариальные опухоли полового тяжа (UTROSCT, тип II), имеющие различные, клинические особенности, иммуногистохимические характеристики и прогноз. Большинство эндометриальных стромальных опухолей с очагами элементов полового тяжа имеют химерные гены, чаще всего JAZF1–SUZ12. Из-за малого числа наблюдений, клинических рекомендаций по их лечению не разработано. Для женщин с UTROSCT, которые хотят сохранить фертильность, возможно рассматривать консервативные лечебные подходы, после тщательного исследования операционного материала. При наличии у пациентки варианта ESTSCLE, при котором имеются сочетание с эндометриальной стромальной саркомой, обязательным является радикальное хирургическое лечение.

Aims: To study data of complex ultrasonic diagnosis of early recurrent cancer based on two options: with ascites and without ascites. Materials and Methods: we examined 88 patients with recurrent ovarian cancer who underwent sonographic examinations. Results: Any changes in the structure of pelvic tissiues (thickening of the pelvic peritoneum, the appearance of the liquid, the appearance of cystic or solid particles) determined by sonography, should be considered as a recurrence of the disease.

Materials end methods. The Federal State Non-Profit Institution of Russian Scientific Center of Radiology and Roentgenology of the Russian Ministry of Health diagnosed and treated 214 women 2002 to 2011. The study only covered serous ovarian cancer. The average age of the patients was 58.8 years. We divided the patients into 2 groups. Group A included 68 patients with localized cancer without clinical evidence of ascites (Ia, Ib, IIa, IIb). Group B included 146 patients with ascites induced by ovarian cancer, with extensive lesions of visceral and parietal peritoneum, with metastasis to the greater omentum (IIc, IIIc). There also was a separate group of 2420 postmenopausal patients who underwent CA-125 screening and ultrasound examination of the lower pelvis. Conclusion. Relatively efficient early diagnosis of ovarian cancer includes the following: CA-125 testing for high risk group patients (enlarged appendage syndrome) 3-4 times per year, or using modern ultrasound systems to evaluate blood flow and vascular architectonics, or a combination of both, CA-125 testing and thorough ultrasound examination. A persistent (within 4-6 weeks) increase in CA-125 levels (> 35ED/ml) in postmenopausal women requires an in-depth examination. Any increase in the postmenopausal ovary size is an indication for surgical treatment.

The aim of this study is to explore the possibilities of modern ultrasound technology for dynamic monitoring of the effectiveness of drug therapy. The analysis of the complex survey of 86 patients, 58 women with cervical cancer (IIb-IIIb stages) and 28 patients with cancer of the ovaries (IIa-IVstages), was performed. All patients in the study groups were at the first stage of complex treatment of chemotherapy. Morphological verification of the diagnosis was made ​​in 100% of cases. Surgical treatment was performed: 52 (90%) patients with cervical cancer and 25 (89%) ovarian cancer. There was a direct correlation between the degree of drug pathomorphism and the volume of the tumor focus, as well as a reduction of vascularization.